IMTX is expected to report earnings to rise 47.06% to -25 cents per share on November 14
Q3'24
Est.
$-0.25
Q2'24
Beat
by $0.11
Q1'24
Beat
by $0.16
Q4'23
Beat
by $0.01
Q3'23
Beat
by $0.04
The last earnings report on August 13 showed earnings per share of -17 cents, beating the estimate of -28 cents. With 839.17K shares outstanding, the current market capitalization sits at 1.02B.
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer